TABLE 5.

Univariate Sensitivity Analysis of ICERs (Cost per Relapse Avoided) for Models 1 and 2

	Input Variable
	Drug Acquisition Cost		Number of Relapses Before Treatment		Cost for Relapse Treatment
	(+)	(-)	(+)	(-)	(+)	(-)
Model 1: PEG ICERS
IM IFN beta-1a	PEG dominated	PEG dominated	PEG dominated	PEG dominated	PEG dominated	PEG dominated
SC IFN beta-1b	PEG vs. SC IFN beta-1b: $2,374,400	PEG vs. SC IFN beta-1b: $1,582,200	PEG vs. SC IFN beta-1b: $1,976,100	PEG vs. SC IFN beta-1b: $1,978,300	PEG vs. SC IFN beta-1b: $1,977,800	PEG vs. SC IFN beta-1b: $1,978,800
GA	PEG dominated	PEG dominated	PEG dominated	PEG dominated	PEG dominated	PEG dominated
FIN	FIN vs. PEG: $70,790	FIN vs. PEG: $47,990	FIN vs. PEG: $49,308	FIN vs. PEG: $74,788	FIN vs. PEG: $58,950	FIN vs. PEG: $59,830
NAT	NAT vs. PEG: $3,015	NAT vs. PEG: $5,415	NAT vs. PEG: $3,200	NAT vs. PEG: $5,700	NAT vs. PEG: $3,375	NAT vs. PEG: $4,656
DMF	DMF vs. PEG: $8,160	DMF vs. PEG: $4,560	DMF vs. PEG: $4,809	DMF vs. PEG: $8,814	DMF vs. PEG: $5,922	DMF vs. PEG: $6,811
Model 2: ALT ICERs
IFN beta-1a 44 μg	ALT vs. IFN beta-1a 44 μg: $29,922	ALT vs. IFN beta-1a 44 μg: $20,631	ALT vs. IFN beta-1a 44 μg: $23,384	ALT vs. IFN beta-1a 44 μg: $32,356	ALT vs. IFN beta-1a 44 μg: $24,957	ALT vs. IFN beta-1a 44 μg: $25,576

ALT = alemtuzumab; DMF = dimethyl fumarate; FIN = fingolimod; GA = glatiramer acetate; ICER = incremental cost-effectiveness ratio; IFN = interferon; IM = intramuscular; NAT = natalizumab; PEG = peginterferon beta-1a; SC = subcutaneous.